Therapeutics and DNA Methylation Inhibitors

S. Bhalla, S. C. Navada

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in the myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefit in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that has led to their approval in hematologic diseases, and future potential uses of these agents both alone and in combination.

Original languageEnglish
Title of host publicationMedical Epigenetics
PublisherElsevier Inc.
Number of pages9
ISBN (Electronic)9780128032404
ISBN (Print)9780128032398
StatePublished - 1 Jul 2016


  • Acute myeloid leukemia
  • Azacitidine
  • DNA methyltransferase inhibitors
  • Decitabine
  • Histone deacetylase inhibitors
  • Hypomethylating agents
  • Myelodysplastic syndromes


Dive into the research topics of 'Therapeutics and DNA Methylation Inhibitors'. Together they form a unique fingerprint.

Cite this